These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18366241)

  • 1. Adequacy of patient information on adverse effects: an assessment of patient information leaflets in the UK.
    Carrigan N; Raynor DK; Knapp P
    Drug Saf; 2008; 31(4):305-12. PubMed ID: 18366241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Communicating the risk of side effects to patients: an evaluation of UK regulatory recommendations.
    Knapp P; Raynor DK; Woolf E; Gardner PH; Carrigan N; McMillan B
    Drug Saf; 2009; 32(10):837-49. PubMed ID: 19722727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Side Effect Risk Communication in Patient Information Leaflets over the Past Decade: Results of a Survey.
    Harris K; Dickinson R; Raynor DK; MacDonald J; Knapp P
    Drug Saf; 2015 Aug; 38(8):721-7. PubMed ID: 26100144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. People's Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England.
    Webster RK; Weinman J; Rubin GJ
    Drug Saf; 2017 Aug; 40(8):743-754. PubMed ID: 28497250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verbal descriptors of the frequency of side effects: implementation of EMA recommendations in patient information leaflets in Poland.
    Olchowska-Kotala A; Uchmanowicz I; Szczepanowski R
    Int J Qual Health Care; 2022 Mar; 34(1):. PubMed ID: 35277713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much information about the benefits of medicines is included in patient leaflets in the European Union? - A survey.
    Dickinson R; Raynor DK; Knapp P; MacDonald J
    Int J Pharm Pract; 2017 Apr; 25(2):147-158. PubMed ID: 27405658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials.
    Kirby N; Shepherd V; Howick J; Betteridge S; Hood K
    Trials; 2020 Jul; 21(1):658. PubMed ID: 32680561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two methods of presenting risk information to patients about the side effects of medicines.
    Knapp P; Raynor DK; Berry DC
    Qual Saf Health Care; 2004 Jun; 13(3):176-80. PubMed ID: 15175486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women's knowledge of taking oral contraceptive pills correctly and of emergency contraception: effect of providing information leaflets in general practice.
    Smith LF; Whitfield MJ
    Br J Gen Pract; 1995 Aug; 45(397):409-14. PubMed ID: 7576845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does the side-effect information in patient information leaflets influence peoples' side-effect expectations? A cross-sectional national survey of 18- to 65-year-olds in England.
    Webster RK; Weinman J; Rubin GJ
    Health Expect; 2017 Dec; 20(6):1411-1420. PubMed ID: 28618140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehension of the description of side effects in drug information leaflets: a survey of doctors, pharmacists and lawyers.
    Ziegler A; Hadlak A; Mehlbeer S; König IR
    Dtsch Arztebl Int; 2013 Oct; 110(40):669-73. PubMed ID: 24167524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It's for your benefit: exploring patients' opinions about the inclusion of textual and numerical benefit information in medicine leaflets.
    Hamrosi K; Dickinson R; Knapp P; Raynor DK; Krass I; Sowter J; Aslani P
    Int J Pharm Pract; 2013 Aug; 21(4):216-25. PubMed ID: 23419118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colposcopy information leaflets: what women want to know and when they want to receive this information.
    Byrom J; Dunn PD; Hughes GM; Lockett J; Johnson A; Neale J; Redman CW
    J Med Screen; 2003; 10(3):143-7. PubMed ID: 14561267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory agencies' recommendations for medicine information leaflets: Are they in line with research findings?
    Young A; Tordoff J; Smith A
    Res Social Adm Pharm; 2018 Feb; 14(2):196-202. PubMed ID: 28285793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consumer medication information in the United States, Europe, and Australia: a comparative evaluation.
    Raynor DK; Svarstad B; Knapp P; Aslani P; Rogers MB; Koo M; Krass I; Silcock J
    J Am Pharm Assoc (2003); 2007; 47(6):717-24. PubMed ID: 18032134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicine information leaflets for non-steroidal anti-inflammatory drugs in Thailand.
    Phueanpinit P; Pongwecharak J; Krska J; Jarernsiripornkul N
    Int J Clin Pharm; 2016 Feb; 38(1):25-9. PubMed ID: 26582482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription information leaflets: a national survey.
    Gibbs S; Waters WE; George CF
    J R Soc Med; 1990 May; 83(5):292-7. PubMed ID: 2380943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient information leaflets: informing or frightening? A focus group study exploring patients' emotional reactions and subsequent behavior towards package leaflets of commonly prescribed medications in family practices.
    Herber OR; Gies V; Schwappach D; Thürmann P; Wilm S
    BMC Fam Pract; 2014 Oct; 15():163. PubMed ID: 25277783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisapride and patient information leaflets.
    Sukkari SR; Sasich LD
    CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
    [No Abstract]   [Full Text] [Related]  

  • 20. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
    Lorimer S; Cox A; Langford NJ
    J Clin Pharm Ther; 2012 Apr; 37(2):148-52. PubMed ID: 21592157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.